Investing.com - UBS lowered its price target on Oracle (NYSE:ORCL) to $325.00 from $380.00 while maintaining a Buy rating, citing concerns about the timing of backlog conversion to revenue. Oracle ...
As Oracle pours billions into AI data centers, enterprises may face rising costs — but Oracle too is in a tight spot, which gives CIOs leverage in negotiations. Oracle’s aggressive AI-driven data ...
Abstract: Molecular biology-based tests are widely used to monitor various activities, such as molecular interaction dynamics, cell health, and in other health studies. At present molecular biology ...
Abstract: A new time domain modeling method for dc–dc switching power converters is introduced: conversion function theory of dc converters. This method is based on the concept of “wanted variables” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback